摘要
凝血酶激活的纤溶抑制物 (Thrombin activatablefibrinolysisinhibitor,简称TAFI) ,作为凝血及纤溶调控因子 ,是近十年来国外医学界研究的热点之一 ;TAFI的基础研究是对经典凝血及纤溶调控机制的重要补充 ;在体内主要由凝血酶、凝血酶调节蛋白、纤溶酶、肝素、胰蛋白酶等物质激活而导致纤溶机制受抑 ,血栓溶解时间延长 ,从而增加血栓形成的危险性。TAFI在体内还参与缓激肽、补体等活性物质的调节。动物血栓模型运用TAFI拮抗剂与溶栓剂联合治疗 ,取得良好效果。国外医学界对TAFI与血液、心血管、内分泌等系统疾病的发病关系已展开广泛研究。
Thrombin activatable fibrinolysis inhibitor (TAFI), as a modulator balancing coagulation and fibrinolysis, is one of high light of medical research in last 10 years. Research on TAFI is an important supplement to classical knowledge connecting the coagulation and fibrinolytic cascades. TAFI is converted into activated TAFI (TAFIa) by thrombin, thrombomodulin, heparin and trypsin in vivo . TAFI can inhibit fibrinolysis and prolong thrombolytic time and so may increase the risk of thrombosis. TAFI is also involved with modulation of the active substances such as bradykinin and complement. Inhibitor of TAFI was used to treat the thrombosis with fibrinolytic agent in animal models with good result. The relationship of TAFI with diseases of hematological system, cardiovascular system, endocrine system and so on have been currently studied.
出处
《基础医学与临床》
CSCD
北大核心
2003年第5期484-489,共6页
Basic and Clinical Medicine
